


The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis



Mariola Kurowska-Stolarska, PhD,^a Manhl K. Hasoo, PhD,^a David J. Welsh, PhD,^b Lynn Stewart, BSc,^a Donna McIntyre, PhD,^a Brian E. Morton, BSc,^a Steven Johnstone, PhD,^a Ashley M. Miller, PhD,^c Darren L. Asquith, PhD,^a Neal L. Millar, MD, PhD,^a Ann B. Millar, MD,^d Carol A. Feghali-Bostwick, PhD,^e Nikhil Hirani, MBChB, PhD,^f Peter J. Crick, PhD,^g Yuqin Wang, PhD,^g William J. Griffiths, PhD,^g Iain B. McInnes, MD, PhD,^a and Charles McSharry, PhD^{a,h} Glasgow, Bristol, Edinburgh, and Swansea, United Kingdom; and Charleston, SC

GRAPHICAL ABSTRACT



Background: Idiopathic pulmonary fibrosis (IPF) is progressive and rapidly fatal. Improved understanding of pathogenesis is required to prosper novel therapeutics. Epigenetic changes contribute to IPF; therefore, microRNAs may reveal novel pathogenic pathways.

Objectives: We sought to determine the regulatory role of microRNA (miR)-155 in the profibrotic function of murine

lung macrophages and fibroblasts, IPF lung fibroblasts, and its contribution to experimental pulmonary fibrosis.

Methods: Bleomycin-induced lung fibrosis in wild-type and miR-155^{-/-} mice was analyzed by histology, collagen, and profibrotic gene expression. Mechanisms were identified by *in silico* and molecular approaches and validated in mouse lung fibroblasts and macrophages, and in IPF lung fibroblasts, using

From ^athe Institute of Infection, Immunity and Inflammation, University of Glasgow, ^bthe Scottish Pulmonary Vascular Unit, University of Glasgow, and ^cthe Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow; ^dthe Academic Respiratory Unit, Learning and Research, University of Bristol, Bristol; ^ethe Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston; ^fthe University of Edinburgh/MRC Centre for Inflammation Research, the Queen's Medical Research Institute, Edinburgh; ^gthe College of Medicine, Swansea University, Swansea; and ^hGreater Glasgow and Clyde Clinical Research and Development, Yorkhill Hospital, Glasgow.

M.K.-S. was supported by Arthritis Research UK (grant no. 19213); A.M.M. was supported by the British Heart Foundation (grant no. FS/08/035/25309). M.K.H. was supported by the Ministry of Higher Education and Scientific Research, Republic of Iraq. B.E.M. was supported by a joint grant (grant no. 657-2012) from Medical Research Scotland and Lamellar Biomedical Ltd, Bellshill, United Kingdom. C.A.F.-B. was supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant nos. P30 AR061271 and K24 AR060297). S.J. was supported by British Pigeon Fanciers' Medical Research Trust. Oxysterol measurement was supported by Biotechnology & Biological Sciences Research Council (grant nos. BB/1001735/1 and BB/L001942/1).

Disclosure of potential conflict of interest: M. K. Hasoo receives research support from the Ministry of Higher Education and Scientific Research. P. J. Crick, Y. Wang, and W. J. Griffiths receive research support from the Biotechnology and Biological Sciences Research Council. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication December 17, 2015; revised August 10, 2016; accepted for publication September 6, 2016.

Available online October 14, 2016.

Corresponding author: Mariola Kurowska-Stolarska, PhD, Or Charles McSharry, PhD, Institute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, G12 8TA Glasgow, United Kingdom. E-mail: Mariola.Kurowska-Stolarska@glasgow.ac.uk. Or: Charles.McSharry@glasgow.ac.uk.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749

© 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<http://dx.doi.org/10.1016/j.jaci.2016.09.021>

loss-and-gain of function assays, and *in vivo* using specific inhibitors.

Results: miR-155^{-/-} mice developed exacerbated lung fibrosis, increased collagen deposition, collagen 1 and 3 mRNA expression, TGF- β production, and activation of alternatively activated macrophages, contributed by deregulation of the miR-155 target gene the liver X receptor (LXR) α in lung fibroblasts and macrophages. Inhibition of LXR α in experimental lung fibrosis and in IPF lung fibroblasts reduced the exacerbated fibrotic response. Similarly, enforced expression of miR-155 reduced the profibrotic phenotype of IPF and miR-155^{-/-} fibroblasts.

Conclusions: We describe herein a molecular pathway comprising miR-155 and its epigenetic LXR α target that when deregulated enables pathogenic pulmonary fibrosis.

Manipulation of the miR-155/LXR pathway may have therapeutic potential for IPF. (J Allergy Clin Immunol 2017;139:1946-56.)

Key words: MicroRNA-155, lung fibrosis, liver X receptor, fibroblasts, alternatively activated macrophages

Idiopathic pulmonary fibrosis (IPF) affects more than 5 million people worldwide and its incidence is increasing.¹ Histology of IPF includes interstitial fibroblastic foci and deposition of collagen-rich extracellular matrix,² and pirfenidone-targeting tissue remodeling has improved therapeutic options.³ However, mechanisms controlling IPF progression remain poorly understood. IPF is associated with age, male sex, and cigarette smoking,⁴ suggesting an epigenetic contribution to pathogenesis.

MicroRNAs (miRs) are 22-nucleotide noncoding RNAs that regulate gene expression.⁵ Single miRs bind 6 to 8 nucleotide complementary sequences, mainly in the 3-prime untranslated region (3'UTR) of target mRNAs, causing degradation or translation inhibition⁶ and can finetune diverse mRNA often within the same biological pathway.⁷ Identifying disease-specific miRs can reveal novel target mRNA/pathways and provide insight into pathogenesis and identify therapeutic targets.

MicroRNA-155 (miR-155) is required for normal immune function^{8,9}; its overexpression is associated with inflammation, autoimmunity,^{8,10} and cancer,¹¹ whereas miR-155-deficient mice develop age-related airway fibrosis.¹² miR-155 may therefore act as a homeostatic rheostat contributing to the onset and duration of inflammation and remodeling. Our hypothesis was that miR-155 attenuates pathways that induce lung remodeling. We revealed exacerbated experimental fibrosis in miR-155^{-/-} mice upon lung injury. A novel miR-155-regulated pathway identified in this context was the liver X receptor alpha (LXR) α , which is an oxysterol-activated transcription factor (NR1H3).¹³

METHODS

Bleomycin-induced lung fibrosis was induced in miR-155^{-/-} and control mice as described.^{14,15} Mouse lung fibroblasts and macrophages were derived from wild-type (WT) and miR-155^{-/-} mice by lung digestion followed by fluorescence-activated cell sorting. Primary lung fibroblasts from patients with IPF (n = 7) and normal controls (n = 8) were obtained and cultured as described.¹⁶ Experimental interventions included transfecting cells with miR-155 mimic or LXR α siRNA, or incubating with LXR agonist/antagonist

Abbreviations used

Arg2:	Arginase 2
Col:	Collagen
IPF:	Idiopathic pulmonary fibrosis
LXR α :	Liver X receptor alpha
miR-155:	MicroRNA-155
3'UTR:	3-Prime untranslated region
22(S)HC:	22(S)-hydroxycholesterol
WT:	Wild-type

or various alarmins. Comprehensive details are provided in this article's Methods section in the Online Repository at www.jacionline.org.

RESULTS

Experimental pulmonary fibrosis is exacerbated by miR-155 deficiency

To evaluate miR-155 epigenetic control of lung fibrosis, we used the murine model of bleomycin-induced inflammation and pulmonary fibrosis.¹⁷ Bleomycin or control PBS was given to miR-155 gene-deleted (miR-155^{-/-}) mice and WT controls. Bleomycin-induced weight loss (Fig 1, A), lung collagen deposition (Fig 1, B), and biomarkers of inflammation (see Table E1 in this article's Online Repository at www.jacionline.org) were exacerbated in miR-155^{-/-} mice compared with WT mice on day 18. This was accompanied by increased lung tissue expression of mRNA for collagen (*Col*)1a (mainly *Coll1a* isoform) and *Col3a1* (Fig 1, C; see Fig E1 in this article's Online Repository at www.jacionline.org), TGF- β (*Tgf- β*) expression, and lung collagen protein (Table E1). The increased bronchoalveolar lavage cell counts in bleomycin-treated miR-155^{-/-} mice (Table E1) were predominantly macrophages with the repair-associated, alternatively activated (M2) phenotype (Fig 1, D) confirmed by increased arginase 2 (*Arg2*), chitinase, and IL-13 receptor α 2 expression, whereas the expression of the classically activated macrophage (M1) phenotype marker, inducible nitric oxide synthase (*Nos2*), remained unchanged. Together, these data demonstrate that miR-155 deficiency exacerbated the pulmonary fibrotic response to bleomycin.

We next investigated the kinetics of lung tissue miR-155 expression in WT mice given bleomycin (Fig 1, E). Expression of miR-155 in mice given PBS remained constant, whereas in response to bleomycin, miR-155 expression decreased at day 1, increased at day 7, and normalized by day 18. To investigate the factors that might regulate these changes, we established that bleomycin incubated *in vitro* with WT murine primary lung fibroblasts was sufficient to dose dependently downregulate the expression of precursor miR-155 at 8 hours (Fig 1, F) and mature miR-155 at 24 hours (see Fig E2, A, in this article's Online Repository at www.jacionline.org). To mimic the effect of exposure to cytokines generated in the damaged lung,^{17,18} miR-155 expression was measured in WT murine primary lung fibroblasts incubated with exogenous alarmins IL-33,¹⁷ IL-25,¹⁹ IL-1 α ,¹⁸ or High mobility group box 1 (HMGB-1)²⁰ released in response to injury. There was no change in response to IL-33, IL-25, or HMGB-1 (Fig E2, B), but IL-1 α increased miR-155 expression (Fig E2, C). Thus, the dynamic expression of miR-155 *in vivo* may reflect a homeostatic role in inflammation and repair in response to tissue injury.




FIG 1. Deficiency of miR-155 exacerbates experimental model of pulmonary fibrosis. **A**, Bleomycin (1 dose intranasal) exacerbated a decrease in body weight. **B**, Lung collagen deposition (turquoise staining) in miR-155^{-/-} mice (n = 8). **C**, miR-155^{-/-} bleo mice show an increase in lung *Col1a1* and *Col3a1* mRNA. **D**, M2 macrophage polarization. **E**, miR-155 is dynamically regulated by bleomycin in WT mice. **F**, Precursor (pre-)miR-155 is decreased in lung fibroblasts of WT mice (pooled n = 5) cultured with bleomycin. *bleo*, Bleomycin. Data shown as mean ± SEM or median and interquartile range. *P < .05.

Prediction analysis identified LXR α as an miR-155 target in the lung

Identifying mRNA targets under the epigenetic control of miR-155 was our strategy to identify cryptic pathways involved in lung fibrosis. We performed *in silico* analysis of predicted and validated conserved mouse and human miR-155 targets (TargetScan

and miRTarBase) along with targets expressed in lungs or described in respiratory or fibrotic diseases (Ingenuity Pathway Analysis database). This integrated approach identified target mRNAs (Table E2), including hypoxia and TGF- β pathways,^{2,21} among which we validated increased expression of *Hif1a*, *Tgf β 2*, and *Smad1* mRNA in lung tissue of miR-155^{-/-} mice given

bleomycin (see Fig E3 in this article's Online Repository at www.jacionline.org). In addition to these recognized profibrotic pathways, we identified LXR α , which has not hitherto been described in lung fibrosis. LXR α has a conserved 3'UTR seed-region sequence (GCAUUA) complementary to miR-155; therefore, we highlighted this as a potential novel pathway to pathogenic fibrosis and this provides the basis of our study.

Endogenous miR-155 targets human LXR α

We recently demonstrated using a reporter assay that synthetic miR-155 could bind mouse *Lxr α* mRNA.²² To confirm that endogenous miR-155 targets human *LXR α* mRNA, we used an MS2-TRAP RNA affinity purification assay.²³ Expression constructs encoding luciferase genes tagged with the MS2-binding domain motif with either intact *LXR α* , or *LXR α* mutated in the 3'UTR microRNA recognition element as a negative control, were transfected into HEK293 cells together with the MS2GFP-expressing plasmid. The empty vector and a construct containing a tandem of 9 miR-155 binding sites (ie, an miR-155 "sponge") were used as negative and positive controls, respectively. MS2-binding domain-containing transcripts were isolated from transfected cells by immunoprecipitation of green fluorescent protein and the enrichment of miR-155 in precipitates was measured by quantitative PCR (Fig 2, A). Transcripts containing WT *LXR α* 3'UTRs showed significant enrichment in miR-155 compared with the mutated sequence, which showed miR-155 levels similar to the empty vector control; thus, endogenous miR-155 could bind to human *LXR α* mRNA. To confirm and extend this observation, we reintroduced miR-155 into miR-155^{-/-} murine lung fibroblasts by transfection with a synthetic miR-155 mimic. After 24-hour culture, cytosolic LXR α protein concentrations (Fig 2, B) were reduced 60% by miR-155. Together, these findings support a functional interaction between miR-155 and *LXR α* mRNA.

LXR α expression and activity are increased in miR-155^{-/-} mice with lung fibrosis

Compared with WT mice given PBS, the expression of *Lxr α* mRNA in lung tissue of WT mice given bleomycin was upregulated on day 1 and had normalized by day 7 (Fig 2, C). This increase was confirmed at the protein level in lung fibroblasts of WT mice given bleomycin, peaking at days 2 and 3 and normalizing to control PBS levels at day 7 (Fig 2, D-F; see Fig E4 in this article's Online Repository at www.jacionline.org). This *in vivo* expression pattern of *Lxr α* was reciprocal to that of miR-155 (Fig 1, E) in WT mice. Consistent with the homeostatic molecular interaction between miR-155 and *Lxr α* mRNA, miR-155^{-/-} mice given bleomycin maintained higher levels of lung *Lxr α* expression compared with WT mice (Fig 2, G). This increased expression was associated with an increase in *Lxr α* activity as measured by the expression of its specific functional reporter *Abca1* in lung tissue mRNA (Fig 2, H). Together, these data demonstrate that the lack of epigenetic homeostatic regulation in miR-155^{-/-} mice was associated with a sustained increase in *Lxr α* expression and activity in response to bleomycin.

Serum concentrations of LXR oxysterol ligands are unchanged in experimental fibrosis

Oxidized derivatives of cholesterol, oxysterols, for example, 24(S) hydroxycholesterol and 27-hydroxycholesterol, are natural

ligands that stimulate the expression and activation of LXR α .²⁴ We showed previously that miR-155^{-/-} mice have higher serum cholesterol concentrations while on a high fat diet²²; therefore, to test whether different oxysterol concentrations in miR-155^{-/-} mice treated with bleomycin were responsible for the *Lxr α* activation and exacerbated lung fibrosis, we profiled serum oxysterols using mass spectrometry (Table E3). We found no differences between any of the known LXR α ligands,^{25,26} suggesting that the increased activation of the *Lxr α* pathway in miR-155^{-/-} mice was due to normal activation of more available LXR α .

miR-155^{-/-} lung fibroblasts and macrophages have an LXR-dependent profibrotic phenotype

We next investigated the role of LXR pathway activation in primary lung fibroblasts and alveolar macrophages. Compared with WT cells, miR-155^{-/-} fibroblasts and macrophages had greater and constitutive expression of the *LXR α* reporter gene, *Abca1* (Fig 2, I), suggesting that the LXR α pathway itself was constitutively activated. In miR-155^{-/-} macrophages, this was associated with an increased profibrotic (M2) phenotype characterized by increased expression of *Arg2*, a key enzyme controlling the bioavailability of hydroxyproline for collagen synthesis²⁷ (Fig 2, J). We demonstrated that this increased *Arg2* expression in miR-155^{-/-} macrophages was restored to normal by *Lxr α* -siRNA (Fig 2, K; see Fig E5, A, in this article's Online Repository at www.jacionline.org) and by LXR antagonist 22(S)-hydroxycholesterol (22(S)HC)²⁸ (Fig 2, L). To extend this to human cells, we investigated the regulatory interrelationship between *LXR α* and miR-155 in the expression of *ARG2* in human macrophages. Healthy human monocyte-derived macrophages were transfected with control siRNA or *LXR α* siRNA, each with miR-155 inhibitor or control inhibitor (Fig E5, C). To induce *LXR α* and *ARG2* expression, the cells were cultured with LXR agonist GW3965 or control dimethyl sulfoxide. The LXR agonist-induced increase in *ARG2* expression was further increased by inhibition of miR-155, and this increase was restored to normal by *LXR α* -specific siRNA (see Fig E6 in this article's Online Repository at www.jacionline.org). Together, these data suggest that LXR α -dependent regulation of *ARG2* was governed by miR-155 in human and mouse macrophages.

We next explored whether miR-155 influenced the profibrotic function of fibroblasts in an LXR α -dependent manner. *In vitro* proliferation, migration, and collagen production were compared in primary lines derived from mouse lung tissue. miR-155^{-/-} fibroblasts displayed greater proliferation to serum supplementation than did WT fibroblasts (Fig 3, A), which was restored to the normal proliferation observed in WT cells by the LXR antagonist 22(S)HC in a dose-dependent manner (Fig 3, B). miR-155^{-/-} fibroblasts also displayed increased migration compared with WT fibroblasts into the scratch space of an *in vitro* wound-healing assay, which was normalized by 22(S)HC (Fig 3, C and D). The increased fibroblast infiltration was not due to proliferation because the culture medium was supplemented with 0.3% FCS, a concentration that did not support fibroblast proliferation (Fig 3, A). miR-155^{-/-} fibroblasts produced approximately 40-fold increased concentration of soluble collagen in culture than did WT fibroblasts in response to 3% FCS (Fig 3, E), which was normalized in a dose-dependent manner by 22(S)HC to concentrations produced by WT fibroblasts (Fig 3, F).




FIG 2. LXR α is regulated by miR-155. **A**, miR-155 binds to human LXR α . HEK293 were transfected with either empty vector (pmiRGLO-MS2BD) or miR-155 sponge (pmiRGLO-MS2BD-miR155Sp) or 3'UTR-LXR α (pmiRGLO-MS2BD-LXR α WT), or MS2 mutated in MRE 3'UTR-LXR α (pmiRGLO-MS2BD-Lxr α -MT), and miR-155 captured in the immunoprecipitate quantified by quantitative PCR. Data presented as mean \pm SEM of 2 technical replicates; representative of 3 experiments. **B**, miR-155 $^{-/-}$ fibroblasts show downregulation of LXR α protein after transfection with miR-155 mimic. **C**, Time course of *Lxr α* mRNA expression in lungs of WT mice after bleomycin (n = 4-7 per group). **D**, Lung fibroblast gating strategy. Representative histograms (**E**) and quantitative evaluation (**F**) of an increase in LXR α expression in lung fibroblasts during fibrosis. Expression of *Lxr α* (**G**) and *Abca1* (**H**) in lungs of WT and miR-155 $^{-/-}$ mice on day 18. **I**, Constitutive expression of *Abca1* in lung fibroblasts (n = 4) and in alveolar macrophages (n = 4). Constitutive expression of *Arg2* in alveolar macrophages (n = 5) (**J**) and after transfection with *Lxr α* siRNA (**K**) or treatment with 22(S)HC (30 μ M) (**L**). Data presented as mean \pm SEM or median and interquartile range. *bleo*, Bleomycin; *MRE*, microRNA recognition element; *DMSO*, dimethyl sulfoxide; *MS2BD*, MS2-binding domain. **P* < .05.




FIG 3. The phenotype of miR-155^{-/-} lung fibroblasts is driven by LXR. **A**, miR-155^{-/-} fibroblasts showed higher proliferation in response to FCS (%S) than did WT fibroblasts (pooled lungs of 4 mice). **B**, LXR antagonist 22(S)HC reduced the proliferation of miR-155^{-/-}. **C** and **D**, miR-155^{-/-} fibroblasts had greater migration capacity; partially inhibited by 22(S)HC, and **(E)** produced more collagen than did WT fibroblasts. Collagen **(F)** and TGF- β production **(G** and **H)** by miR-155^{-/-} fibroblasts was inhibited by 22(S)HC (Fig 3, G) and by miR-155 mimic (Fig 3, H). **I**, *Arg2* was higher in miR-155^{-/-} than in WT fibroblasts and this was reduced by LXR α siRNA. Data are presented as mean \pm SEM of 4 biological replicates. DMSO, Dimethyl sulfoxide. **P* < .05.

TGF- β is the principal cytokine driving collagen gene expression, and oxysterol agonists of LXR can induce TGF- β production.^{29,30} Therefore, to investigate the role of miR-155 in LXR α -dependent collagen production, we quantified TGF- β in WT and miR-155^{-/-} fibroblast supernatants cultured for 48 hours in 3% FCS, with/without 22(S)HC. miR-155^{-/-} fibroblasts produced higher concentrations of TGF- β than did WT fibroblasts and this increase was inhibited either by LXR antagonism (Fig 3, G) or by restoring miR-155 by transfection (Fig 3, H; see Fig E5, B). To investigate whether arginase was involved in this process, we measured the expression of *Arg2* in fibroblasts that were transfected with *Lxr α* siRNA or control siRNA (Fig E5, B). miR-155^{-/-} fibroblasts had higher expression levels of *Arg2* than did WT fibroblasts (Fig 3, I), and specific inhibition of *Lxr α* by siRNA restored *Arg2* expression in miR-155^{-/-} fibroblasts to the normal levels of WT fibroblasts. These observations indicate that excessive production of soluble collagen by miR-155^{-/-} fibroblasts may be due to an

LXR-dependent increase in TGF- β and increased arginase-driven production of hydroxyproline.

The exacerbated bleomycin-induced lung fibrosis in miR-155^{-/-} mice is LXR-dependent

To test the involvement of LXR in experimental lung fibrosis, miR-155^{-/-} and WT mice were given bleomycin or control PBS, and treated with the LXR antagonist 22(S)HC or control cyclo-dextrin excipient. The subsequent loss of body weights for miR-155^{-/-} and WT mice is shown on different panels for clarity in Fig 4, A. The exacerbated bleomycin-induced weight loss in miR-155^{-/-} mice was mitigated by treatment with 22(S)HC to the weight loss seen in WT mice given bleomycin, as was the exacerbated lung tissue collagen deposition (Fig 4, B), and the inflammatory bronchoalveolar lavage cytology (see Fig E7 in this article's Online Repository at www.jacionline.org). The miR-155^{-/-}-associated increased lung tissue *Colla1*, *Col3a1*, and




FIG 4. Inhibition of LXR ameliorates lung fibrosis in miR-155^{-/-} mice. From 2 days before the administration of bleomycin (n = 10), mice were treated with daily injections of 22(S)HC. Weight loss (**A**) and collagen deposition (**B**) (turquoise) in miR-155^{-/-} mice was mitigated by 22(S)HC. The expression of *Col1a1*, *Col3a1*, and *Arg2* in lung tissues (**C**) and *Arg2* (**D**) in BAL cells in miR-155^{-/-} mice was reduced by 22(S)HC. Data presented as mean ± SEM or median (interquartile range). BAL, Bronchoalveolar lavage. *P < .05.

Arg2, and the bronchoalveolar lavage cell *Arg2* mRNA expression were also attenuated by 22(S)HC (Fig 4, C and D). 22(S)HC had no significant effect on weight loss in bleomycin-treated WT mice (Fig 4, B). These data demonstrate that the exacerbated inflammatory and fibrotic response to bleomycin in miR-155^{-/-} mice is at least partly dependent on LXR α and tractable *in vivo* by LXR antagonism.

The exacerbated profibrotic behavior of IPF fibroblasts is normalized by neutralization of the LXR pathway

To investigate the contribution of LXR pathway activation to the exacerbated lung tissue–remodeling characteristic of IPF, we obtained primary lung fibroblast lines from patients with IPF and

control subjects (details in Tables E4 and E5). The constitutive cytosolic LXR α protein concentration was greater in IPF than in normal lung fibroblasts (Fig 5, A). IPF lung fibroblasts showed increased collagen synthesis *in vitro* compared with control lung fibroblasts, which could be either reduced in a dose-dependent manner by LXR antagonist (Fig 5, B) or further increased by the LXR agonist GW3965 (Fig 5, C). The contribution of LXR activation to the excess collagen production by IPF fibroblasts was further confirmed by transfecting IPF lung fibroblasts with LXR α siRNA (Fig E5, D), which attenuated the collagen production (Fig 5, D).

Control normal and IPF fibroblasts produced TGF- β in culture supernatants; however, only IPF fibroblasts increased TGF- β production in response to 1% FCS supplementation and this increased production was inhibited by LXR antagonist (Fig 5, E).




FIG 5. The profibrotic phenotype of IPF fibroblasts can be normalized by neutralization of LXR. Synchronized normal ($n = 4$) and IPF ($n = 6$) primary lung fibroblasts were cultured with 1% FCS (%S). **A**, IPF fibroblasts contained higher concentrations of LXR α protein. **B**, Collagen production by IPF fibroblasts was (Fig 5, **B**) reduced by 22(S)HC or potentiated by GW3965 (**C**). **D**, LXR α siRNA reduced collagen production by IPF fibroblasts. **E**, 22(S)HC inhibited TGF- β production. **F**, GW3965 potentiated serum-induced ARG2 expression by IPF fibroblasts. **G**, LXR α siRNA reduced ARG2 expression by IPF fibroblasts. Data are presented as mean \pm SEM of 4 biological replicates. * $P < .05$.

Normal and IPF fibroblasts constitutively expressed similar levels of ARG2 mRNA; however, only IPF fibroblasts showed higher expression of ARG2 after stimulation with LXR agonist GW3965 (Fig 5, *F*) and this increased ARG2 expression was attenuated by transfection with LXR α siRNA (Fig 5, *G*). These data indicate that TGF- β and ARG2 are regulated in an LXR α -dependent manner in IPF fibroblasts. In addition, compared with control lung fibroblasts, IPF lung fibroblasts showed greater *in vitro* proliferation in response to 1% FCS supplementation, which was reduced by LXR antagonist (see Fig E8, *A*, in this article's Online Repository at www.jacionline.org). IPF lung fibroblasts had increased migratory capacity into the scratch space of an *in vitro* wound-healing assay, compared with normal lung fibroblasts, and this increased migration was reduced to levels of normal fibroblasts by LXR antagonism (Fig E8, *B* and *C*). Thus, activation of the LXR pathway may drive the excessive profibrotic phenotypic characteristics of IPF fibroblasts.

LXR α is deregulated from miR-155 in IPF lung fibroblasts

To test whether the LXR α -dependent collagen production by IPF fibroblasts was regulated by miR-155, control and IPF fibroblasts were transfected with miR-155 and stimulated by synthetic LXR agonist GW3965 *in vitro*. The increased collagen production by IPF fibroblasts was decreased (see Fig E9, *A*, in this article's Online Repository at www.jacionline.org), suggesting that collagen synthesis, as the prime exemplar of the LXR α -dependent profibrotic function of IPF fibroblasts, can be regulated by miR-155.

Because constitutively increased LXR α expression (Fig 5, *A*) and activity contributed to IPF fibroblast phenotype, we investigated whether this was caused by altered serum concentrations of LXR α oxysterol ligands in patients with IPF or by altered miR-155 expression. Comparing serum oxysterol concentrations in IPF and control subjects showed no differences in any of the LXR α ligands tested (Table E6). The constitutive miR-155 expression in IPF fibroblasts was similar to that of control lung fibroblasts (Fig E9, *B*); therefore, we investigated whether the increased LXR α expression and activation in IPF fibroblasts was due to a deregulated interaction between miR-155 and LXR α . Because the consequence of LXR α deregulation resulting in exacerbated lung fibrosis became apparent in miR-155^{-/-} mice only when stressed with bleomycin, we compared the dynamic interaction between miR-155 and LXR α in control and IPF fibroblasts cultured under the hypoxic stress (1% O₂) that mimics the lung environment in IPF.³¹ Compared with normoxia, miR-155 expression was increased by hypoxia in both healthy and IPF fibroblasts (Fig E9, *C*); however, LXR α and ABCA1 expression was increased by hypoxia only in IPF fibroblasts (Fig E9, *D*), suggesting selective deregulation of LXR α function. To explore the dynamics of the interaction between miR-155 and LXR α , we correlated the ratio of their relative expressions in normal and IPF lung fibroblasts. The relative expression levels of LXR α and miR-155 in normal and IPF lung fibroblasts cultured under normoxic conditions showed no significant correlation (Spearman ρ and 95% CI): normal fibroblasts $r = 0.263$ (-0.310 to 0.69) and IPF fibroblasts $r = 0.439$ (-0.072 to 0.767). However, under hypoxic conditions, there was a negative correlation in normal fibroblasts $r = -0.655$ (-0.868 to -0.236)




FIG 6. Deregulation of the miR-155/LXR α axis contributes to exacerbated pulmonary fibrosis. TGF- β , Transforming growth factor β .

that was not apparent in IPF fibroblasts $r = -0.152$ (-0.602 to 0.375) (Fig E9, E). This suggested that there was tight posttranscriptional control of LXR α expression by homeostatic miR-155 in response to a stressor such as hypoxia in normal fibroblasts that was lost in IPF fibroblasts, potentially contributing to the deregulated LXR α activity.

The mechanism of this deregulation may be due to increased competitive miR-155 binding by other mRNA targets that contain multiple miR-155 seed-region binding sites.⁷ To test this hypothesis, we evaluated the expression of a validated miR-155 target *ZNF652*³² that contains 7 miR-155 binding sites (HumanTargetScan v7.0) in normal and IPF fibroblasts cultured in normoxia and hypoxia. *ZNF652* was upregulated by hypoxia in IPF but not in normal lung fibroblasts (Fig E9, F) and in contrast to *LXR α* , the expression of *ZNF652* correlated negatively with miR-155 expression (Fig E9, G), suggesting that under hypoxic stress, miR-155 may be preferentially bound by the increased *ZNF652* leading to derepression of LXR α in IPF fibroblasts.

DISCUSSION

Characteristic IPF fibrosis is refractory to anti-inflammatory therapy⁴ and antifibrotic drugs underline the primacy of aberrant wound healing to pathogenesis.³ We provide new understanding of this process. Mouse models and IPF lung fibroblasts had constitutively increased *LXR α* transcription when deregulated from homeostatic miR-155, associated with LXR-dependent excessive fibrotic phenotype mediated by increased TGF- β , arginase, and collagen production that could be mitigated by LXR antagonist (Fig 6).

Expression of miR-155 is rapidly and transiently reduced in WT mice after bleomycin, associated with transient reciprocally increased *Lxr α* expression and protein, and the remodeling is self-limiting.¹⁵ In contrast, miR-155^{-/-} mice have constitutively increased *Lxr α* and an exacerbated lung fibrosis, and this difference may provide novel insight into mechanisms of relentless lung remodeling. IPF lung fibroblasts also have constitutively

more LXR α protein (and upregulated *LXR α* and *ABCA1*: IPF data repositories GSE2052³³ and GEOD-24206³⁴), and greater LXR-dependent profibrotic activation that was normalized by miR-155 overexpression, *LXR α* gene silencing, or metabolic antagonism of LXR α activity using 22(S)HC.

LXR may exert profibrotic effects by inducing *Arg2* and *Tgf β* expression. The *Arg2* promoter contains an LXR response element and is activated by LXR agonism in macrophages,³⁵ and we extend this finding to mouse and human fibroblasts. *Arg2* is the mitochondrial form involved in hydroxyproline production and is essential for collagen biosynthesis. Upregulated *Arg2* in miR-155^{-/-} macrophages and fibroblasts is normalized by inhibition of *Lxr α* by siRNA, or its activity by metabolic antagonism. LXR may also exert profibrotic effects by similarly regulating TGF- β expression, and the excessively high concentrations of TGF- β produced *in vitro* by miR-155^{-/-} and IPF fibroblasts were normalized by LXR antagonism.

Our profibrotic LXR function in lung conflicts with the antifibrotic function of T0901317-LXR activation in skin during experimental systemic sclerosis model.³⁶ This can be reconciled; synthetic ligand T0901317 locks LXR into the conformation that recruits coactivators, whereas natural oxysterol ligands and GW3965 induce the flexible conformation that binds coactivators and corepressors,³⁷ and there are tissue-specific epigenetic changes in chromatin that determine LXR-driven gene expression.³⁸ Furthermore, the multiple-dose bleomycin-induced skin fibrosis is driven by IL-6 from inflammatory macrophages inhibited by LXR activation,³⁶ whereas, in contrast, our single-bolus bleomycin-induced lung fibrosis is associated with repair M2 macrophage activation (Fig 1, D¹⁷), which is enhanced by LXR activation.^{35,39} Alveolar macrophages are uniquely enriched in genes of lipid metabolism that are cross-regulated by LXR, supporting their role in lung homeostasis.⁴⁰

The cryptic involvement of LXR α in fibrosis became apparent when deregulated in miR-155^{-/-} mice plus the stressor of bleomycin. The mechanism of *LXR α* deregulation in IPF fibroblasts may be due to ineffective regulation by miR-155, which becomes

apparent under hypoxic stress equivalent to the IPF lung environment.³¹ IPF and control lung fibroblasts had similar miR-155 expression when cultured under normal oxygen tensions. Under hypoxic conditions, the expression levels of miR-155 correlated negatively with *LXRα* in control lung fibroblasts, implying tight epigenetic control, whereas there was no equivalent engagement between miR-155 and *LXRα* in IPF fibroblasts, thus enabling continued *LXRα* autoactivation⁴¹ and profibrotic behavior. This deregulation might be mediated by several mechanisms,³⁸ including competition for available miR-155 by other targets with the AGCAUAAA seed-region⁷ as validated in cancer cells.⁴² One strong miR-155 candidate target mRNA is *ZNF652*, which has 7 seed-region binding sites. *ZNF652* is induced by hypoxia in IPF but not normal fibroblasts. We identified that in contrast to *LXRα*, its increased expression negatively correlated with miR-155 in IPF fibroblasts, suggesting that *ZNF652* mRNA competitively bound miR-155 leading to derepression of *LXRα*.

Expression of miR-155 has been identified as increased⁴³ or reduced,⁴⁴ and serum miR-155 levels were normal⁴⁵ in IPF. This may reflect the dynamism of miR-155 expression in experimental IPF. In lung tissue, it is transiently downregulated by bleomycin (Fig 1, F) and TGF-β,⁴⁶ and induced by inflammatory mediators, for example, IL-1α (Fig E2, C) or hypoxia,⁴⁷ as a counterbalance mechanism regulating homeostatic lung tissue repair.

Fibrosis of the lung is a common comorbidity of systemic sclerosis. The pathogenesis and clinical features of the autoimmune and inflammation-driven lung pathology of systemic sclerosis differs from IPF⁴⁸ and 2 recent studies describe a pathogenic role for miR-155 in the experimental skin and lung fibrosis associated with systemic sclerosis.^{49,50} This reflects the dual role of miR-155 driving chronic inflammation-associated pathologies and resolving fibrosis that we found aberrant in IPF.

Key messages

- Deficiency of miR-155 exacerbates bleomycin-induced experimental pulmonary fibrosis.
- In the absence of miR-155 epigenetic control, *LXRα* activity is deregulated in mouse primary lung fibroblasts facilitating increased collagen and TGF-β production, and in macrophages enhancing alternative activation, each inhibited by *LXR* antagonism, *LXRα* gene silencing, or exogenous miR-155 mimic.
- The exacerbated bleomycin-induced pulmonary fibrosis in miR-155^{-/-} mice was mitigated *in vivo* by *LXR* antagonism.
- Primary IPF lung fibroblasts had constitutively raised *LXRα*, deregulated from miR-155, and their profibrotic phenotype was inhibited by *LXR* antagonism, *LXRα* gene silencing, or exogenous miR-155 mimic.

REFERENCES

1. Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. *Chest* 2013;143:1078-84.
2. Wynn TA. Integrating mechanisms of pulmonary fibrosis. *J Exp Med* 2011;208:1339-50.

3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014;370:2083-92.
4. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. *Lancet* 2011;378:1949-61.
5. Ruvkun G. Molecular biology: glimpses of a tiny RNA world. *Science* 2001;294:797-9.
6. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature* 2005;433:769-73.
7. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. *Nat Rev Genet* 2012;13:271-82.
8. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. *Proc Natl Acad Sci U S A* 2011;108:11193-8.
9. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. *Science* 2007;316:604-8.
10. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. *Immunity* 2010;33:607-19.
11. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. *J Exp Med* 2008;205:585-94.
12. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. *Science* 2007;316:608-11.
13. Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. *Trends Pharmacol Sci* 2012;33:394-404.
14. Moeller A, Ask K, Warburton D, Gaudie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? *Int J Biochem Cell Biol* 2008;40:362-82.
15. B Moore B, Lawson WE, Oury TD, Sisson TH, Raghavendran K, Hogaboam CM. Animal models of fibrotic lung disease. *Am J Respir Cell Mol Biol* 2013;49:167-79.
16. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. *Am J Pathol* 2005;166:399-407.
17. Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. *J Allergy Clin Immunol* 2014;134:1422-32.e11.
18. Suwara MI, Green NJ, Borthwick LA, Mann J, Mayer-Barber KD, Barron L, et al. IL-1α released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. *Mucosal Immunol* 2014;7:684-93.
19. Hams E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, Cooke G, et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. *Proc Natl Acad Sci U S A* 2014;111:367-72.
20. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. *Am J Respir Crit Care Med* 2008;178:822-31.
21. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 2012;18:1028-40.
22. Miller AM, Gilchrist DS, Nijjar J, Araldi E, Ramirez CM, Lavery CA, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. *PLoS One* 2013;8:e72324.
23. Yoon JH, Srikantan S, Gorospe M. MS2-TRAP (MS2-tagged RNA affinity purification): tagging RNA to identify associated miRNAs. *Methods* 2012;58:81-7.
24. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signaling pathway mediated by the nuclear receptor LXR alpha. *Nature* 1996;383:728-31.
25. Song C, Liao S. Cholestenic acid is a naturally occurring ligand for liver X receptor alpha. *Endocrinology* 2000;141:4180-4.
26. Griffiths WJ, Crick PJ, Wang Y, Ogundare M, Tuschl K, Morris AA, et al. Analytical strategies for characterization of oxysterol lipidomes: liver X receptor ligands in plasma. *Free Radic Biol Med* 2013;59:69-84.
27. Endo M, Oyadomari S, Terasaki Y, Takeya M, Suga M, Mori M, et al. Induction of arginase I and II in bleomycin-induced fibrosis of mouse lung. *Am J Physiol Lung Cell Mol Physiol* 2003;285:L313-21.
28. Tranheim Kase E, Nikolic N, Pettersen Hessvik N, Fjeldheim AK, Jensen J, Thoresen GH, et al. Dietary supplementation with 22-S-hydroxycholesterol to rats

- reduces body weight gain and the accumulation of liver triacylglycerol. *Lipids* 2012;47:483-93.
29. Schwartz Y, Khoshchenko OM, Dushkin MI, Feofanova NA. Effects of cholesterol and nuclear hormone receptor agonists on the production of transforming growth factor-beta in macrophages. *Bull Exp Biol Med* 2009;148:406-9.
 30. Kikuchi T, Sugiura H, Koarai A, Ichikawa T, Minakata Y, Matsunaga K, et al. Increase of 27-hydroxycholesterol in the airways of patients with COPD: possible role of 27-hydroxycholesterol in tissue fibrosis. *Chest* 2012;142:329-37.
 31. Tzouveleki A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G, et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. *Am J Respir Crit Care Med* 2007;176:1108-19.
 32. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. *Oncogene* 2013;32:2992-3000.
 33. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Cav-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. *J Exp Med* 2006;203:2895-906.
 34. Meltzer EB, Barry WT, D'Amico TA, Davis RD, Lin SS, Onaitis MW, et al. Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle. *BMC Med Genomics* 2011;4:70.
 35. Marathe C, Bradley MN, Hong C, Lopez F, Ruiz de Galarreta CM, Tontonoz P, et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. *J Biol Chem* 2006;281:32197-206.
 36. Beyer C, Huang J, Beer J, Zhang Y, Palumbo-Zerr K, Zerr P, et al. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. *Ann Rheum Dis* 2015;74:1317-24.
 37. Albers M, Blume B, Schlueter T, Wright MB, Kober I, Kremoser C, et al. A novel principle for partial agonism of liver X receptor ligands: competitive recruitment of activators and repressors. *J Biol Chem* 2006;281:4920-30.
 38. Steffensen KR, Jakobsson T, Gustafsson JA. Targeting liver X receptors in inflammation. *Expert Opin Ther Targets* 2013;17:977-90.
 39. Hasty AH, Yvan-Charvet L. Liver X receptor alpha-dependent iron handling in M2 macrophages: the missing link between cholesterol and intraplaque hemorrhage? *Circ Res* 2013;113:1182-5.
 40. Gautier EL, Shay T, Miller J, Greter M, Jakubczik C, Ivanov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. *Nat Immunol* 2012;13:1118-28.
 41. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, et al. Autoregulation of the human liver X receptor alpha promoter. *Mol Cell Biol* 2001;21:7558-68.
 42. Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMG2 functions as a competing endogenous RNA to promote lung cancer progression. *Nature* 2014;505:212-7.
 43. Pandit KV, Corcoran D, Yousef H, Yarlaga M, Tzouveleki A, Gibson KF, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2010;182:220-9.
 44. Cho JH, Gelinas R, Wang K, Etheridge A, Piper MG, Batte K, et al. Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. *BMC Med Genomics* 2011;4:8.
 45. Li P, Zhao GQ, Chen TF, Chang JX, Wang HQ, Chen SS, et al. Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis. *J Asthma* 2013;50:960-4.
 46. Pottier N, Maurin T, Chevalier B, Puissegur MP, Lebrigand K, Robbe-Sermesant K, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. *PLoS One* 2009;4:e6718.
 47. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. *Nat Rev Immunol* 2010;10:111-22.
 48. Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? *Arthritis Rheum* 2014;66:1967-78.
 49. Christmann RB, Wooten A, Sampaio-Barros P, Borges CL, Carvalho CR, Kairalla RA, et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. *Arthritis Res Ther* 2016;18:155.
 50. Yan Q, Chen J, Li W, Bao C, Fu Q. Targeting miR-155 to treat experimental scleroderma. *Sci Rep* 2016;6:20314.